-
Product Insights
Plague – Drugs In Development, 2023
Global Markets Direct’s, ‘Plague - Drugs In Development, 2023’, provides an overview of the Plague pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Typhoid Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Typhoid Fever - Drugs In Development, 2023’, provides an overview of the Typhoid Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Burkholderia Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Burkholderia Infections - Drugs In Development, 2023’, provides an overview of the Burkholderia Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gonorrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Gonorrhea - Drugs In Development, 2023’, provides an overview of the Gonorrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gonorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Bacterial Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bacterial Sepsis - Drugs In Development, 2023’, provides an overview of the Bacterial Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacterial Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mycobacterium avium Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium avium Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium avium Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium avium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Osteomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteomyelitis - Drugs In Development, 2023’, provides an overview of the Osteomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cholera – Drugs In Development, 2023
Global Markets Direct’s, ‘Cholera - Drugs In Development, 2023’, provides an overview of the Cholera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2023’, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...